Corrado Advisors’s Cardiff Oncology CRDF Stock Holding History

Corrado Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-278	Closed	-$15K	–	117
2017 Q3	$15K	Buy	+278	New	+$17.3K	0.01%	116

Other funds holding CRDF

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Elkhorn Partners Omaha, Nebraska $117M AUM 28.12% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Corrado Advisors's CRDF Position: Q4 2017 in Review

Corrado Advisors sold out of Cardiff Oncology (CRDF) in Q4 2017, closing a stake of 278 shares — an estimated $15K sold.

Corrado Advisors first reported a position in CRDF in Q3 2017 and held it in 1 quarter. The position peaked at $15K in Q3 2017. 38 funds tracked by Wall St. Rank hold CRDF as of Q4 2017.

Corrado Advisors reported no remaining Cardiff Oncology position as of Q4 2017 after selling out during the quarter.
Corrado Advisors sold 278 Cardiff Oncology shares in Q4 2017, an estimated $15K.
Corrado Advisors first reported a position in Cardiff Oncology in Q3 2017 and held it in 1 quarter.
Corrado Advisors's Cardiff Oncology position peaked at $15K in Q3 2017.
38 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2017.

Based on Corrado Advisors's 13F filing for Q4 2017, filed 10 Jan 2018.